| Literature DB >> 24083511 |
Haribalan Perumalsamy1, Moon Young Jung, Seung Min Hong, Young-Joon Ahn.
Abstract
BACKGROUND: The growth-inhibiting and morphostructural effects of seven constituents identified in Asarum heterotropoides root on 14 intestinal bacteria were compared with those of the fluoroquinolone antibiotic ciprofloxacin.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24083511 PMCID: PMC3850407 DOI: 10.1186/1472-6882-13-245
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
List of human intestinal bacteria tested for growth inhibitory activity
| Gram-positive | Gram-positive |
| | |
| | |
| | |
| Gram-negative | |
| | |
| | |
aHarmful bacteria.
bNonpathogenic bacteria.
cLactic acid-producing bacteria.
dAcidulating bacterium.
Minimal inhibitory concentrations (MICs) of fractions obtained from the solvent hydrolyzable of the methanol extract of root against harmful and nonpathogenic intestinal bacteria using a microtiter plate-based antibacterial bioassay
| | | ||||||
|---|---|---|---|---|---|---|---|
| ME | 14.70 bA | 7.35 cB | 7.35 cB | 14.70 bA | 7.35 bB | 14.70 bA | 7.35 bB |
| HSF | 7.35 cB | 14.70 bA | 7.35 cB | 7.35 cB | 3.67 cC | 7.35 cB | 3.67 cC |
| CSF | 14.70 bA | 14.70 bA | 14.70 bA | 7.35 cB | 7.35 bB | 14.70 bA | 7.35 bB |
| EASF | 7.35 cB | 7.35 cB | 14.70 bA | 7.35 cB | 1.83 dC | 14.70 bA | 7.35 bB |
| BSF | 29.40 aB | 58.80 aA | 29.40 aB | 29.40 aB | 58.80 aA | 58.80 aA | 14.70 aC |
| WSF | NAe | NA | NA | NA | NA | NA | NA |
Means in a column followed by the same lowercase letter and means in a row followed by the same uppercase letter are not significantly different (P > 0.05; Bonferroni test).
aME, methanol extract; HSF, hexane-soluble fraction; CSF, chloroform-soluble faction; EASF, Ethyl acetate-soluble fraction; BSF, butanol-soluble fraction; WSF, water-soluble fraction.
bCd, C. difficile ATCC 9689; Cm, C. paraputiricum ATCC 25780; Cp, C. perfringens ATCC 13124; Sa, S. aureus ATCC 12600.
cBf, B. fragilis ATCC 25285; Ec, E. coli ATCC 11775; St, S. enterica serovar Typhimurium ATCC 13311.
dNonpathogenic bacteria.
eNo activity.
Minimal inhibitory concentrations (MICs) of fractions obtained from the solvent hydrolyzable of the methanol extract of root against beneficial Gram-positive intestinal bacteria using a microtiter plate-based antibacterial bioassay
| | |||||||
|---|---|---|---|---|---|---|---|
| ME | 60.67 aA | 58.50 bB | 58.50 aB | 58.50 aB | 29.30 bC | 58.50 aB | 58.50 aB |
| HSF | 29.30 dB | 29.30 cB | 29.30 bB | 29.30 bB | 29.30 bB | 58.50 aA | 29.30 bB |
| CSF | 55.87 cB | 58.50 bA | 58.50 aA | 29.30 bC | 29.30 bC | 58.50 aA | 58.50 aA |
| EASF | 58.50 bB | 117.0 aA | 58.50 aB | 58.50 aB | 58.50 aB | 55.87 bC | 58.50 aB |
| BSF | NAd | NA | NA | NA | NA | NA | NA |
| WSF | NA | NA | NA | NA | NA | NA | NA |
Means in a column followed by the same lowercase letter and means in a row followed by the same uppercase letter are not significantly different (P > 0.05; Bonferroni test).
aME, methanol extract; HSF, hexane-soluble fraction; CSF, chloroform-soluble faction; EASF, Ethyl acetate-soluble fraction; BSF, butanol-soluble fraction; WSF, water-soluble fraction.
bLactic acid-producing bacteria: Bb, B. bifidum ATCC 29521; Bi, B. infantis ATCC 25962; Be, B. breve ATCC 15700; Bl, B. longum ATCC 15707; La, L. acidophilius ATCC 4356; Lc, L. casei ATCC 393.
cAcidulating bacteria: Cb, C. butyricum ATCC 25779.
dNo activity.
Figure 1Active principles of root. Structures of safrole (1), methyleugenol (2), 1,8-cineole (3), α-asarone (4), δ-3-carene (5), (−)-asarinin (6), and pellitorine (7).
Minimal inhibitory concentrations (MICs) of root constituents against five harmful and two nonpathogenic intestinal bacteria using a microtiter plate-based antibacterial bioassay
| | |||||||
|---|---|---|---|---|---|---|---|
| δ-3-Carene | 0.70 cB | 0.70 eB | 0.70 dB | 0.18 cC | 0.70 cB | 0.18 dC | 2.94 bA |
| Methyleugenol | 0.70 cD | 1.47 dC | 5.80 bA | 2.94 aB | 2.94 aB | 1.47 cC | 1.47 cC |
| 1,8-Cineole | 1.47 bB | 1.47 dB | 2.94 cA | 1.47 bB | 2.94 aA | 2.94 bA | 2.94 bA |
| Pellitorine | 2.94 aA | 1.47 dB | 0.70 dC | 1.47 bB | 2.94 aA | 1.47 cB | 1.47 cB |
| (−)-Asarinin | 2.94 aA | 2.94 cA | 2.94 cA | 2.94 aA | 2.94 aA | 2.94 bA | 1.47 cB |
| α-Asarone | 2.94 aC | 5.80 bB | 12.0 aA | 1.47 bD | 1.47 bD | 2.94 bC | 1.47 cD |
| Safrole | 2.94 aD | 23.50 aA | 2.94 cD | 2.94 aD | 1.47 bE | 7.20 aC | 12.0 aB |
| Ciprofloxacin | 0.25 dA | 0.125 fB | 0.125 eB | 0.063 dC | 0.125 dB | 0.063 eC | 0.063 dC |
Means in a column followed by the same lowercase letter and means in a row followed by the same uppercase letter are not significantly different (P > 0.05; Bonferroni test).
aCd, C. difficile ATCC 9689; Cm, C. paraputiricum ATCC 25780; Cp, C. perfringens ATCC 13124; Sa, S. aureus ATCC 12600.
bBf, B. fragilis ATCC 25285; Ec, E. coli ATCC 11775; St, S. enterica serovar Typhimurium ATCC 13311.
cNonpathogenic bacteria.
Minimal inhibitory concentrations (MICs) of root constituents against seven beneficial Gram-positive intestinal bacteria using a microtiter plate-based antibacterial bioassay
| | |||||||
|---|---|---|---|---|---|---|---|
| δ-3-Carene | 12.0 cA | 5.80 cB | 12.0 aA | 12.0 aA | 12.0 bA | 12.0 aA | 0.70 eC |
| Methyleugenol | 23.50 aA | 23.50 aA | 5.80 bC | 1.47 cD | 12.0 bB | 1.47 cD | 23.50 aA |
| 1,8-Cineole | 23.50 aA | 12.0 bB | 2.94 cC | 2.94 bC | 12.0 bB | 2.94 bC | 12.0 bB |
| Pellitorine | 2.94 eB | 5.80 cA | 2.94 cB | 1.47 cC | 2.94 dB | 1.47 cC | 1.47 dC |
| (−)-Asarinin | 5.80 dA | 5.80 cA | 5.80 bA | 1.47 cC | 5.80 cA | 1.47 cC | 2.94 cB |
| α-Asarone | 12.0 cA | 12.0 bA | 5.80 bB | 1.47 cC | 12.0 bA | 1.47 cC | 12.0 bA |
| Safrole | 22.70 bB | 23.50 aA | 12.0 aC | 12.0 aC | 22.70 aB | 12.0 aC | 23.50 aA |
| Ciprofloxacin | 0.031 fB | 0.031 dB | 0.031 dB | 0.063 dA | 0.063 eA | 0.063 dA | 0.031 fB |
Means in a column followed by the same lowercase letter and means in a row followed by the same uppercase letter are not significantly different (P > 0.05; Bonferroni test).
aLactic acid-producing bacteria: Bb, B. bifidum ATCC 29521; Bi, B. infantis ATCC 25962; Be, B. breve ATCC 15700; Bl, B. longum ATCC 15707; La, L. acidophilius ATCC 4356; Lc, L. casei ATCC 393.
bAcidulating bacterium: Cb, C. butyricum ATCC 25779.
Figure 2Effect on morphostructural changes in test microorganisms. Scanning electron micrographs of two Gram-positives (A)Clostridium perfringens ATCC 13124 and (B)Staphylococcus aureus ATCC 12600 and a Gram-negative (C)Escherichia coli ATCC 11775 without or with treatment of the test compounds. White triangles indicate the morphological changes in cells of the test bacteria treated with corresponding compounds: A1, untreated, well divided and rod-shaped cells; A2, undivided, growth inhibited cells; A3, undivided, growth inhibited cells; A4, cell wall and cytoplasmic membrane disruption; A5, growth inhibited cells with cytoplasmic membrane disruption. B1, untreated, smooth and spherical shaped cells; B2, undeveloped cells with cytoplasmic membrane disruption; B3, cells with damaged cell membrane surface; B4, growth inhibited cells with membrane disruption; B5, undivided cells with collision. C1, untreated, well divided elongated cells; C2, wrinkled shaped cells; C3, growth inhibited cells; C4, growth inhibited cells with membrane disruption; C5; growth inhibited cells with collision.